Project
Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) ½ inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: A randomized placebo-controlled double-blind phase II trial
Completed · 2010 until 2012
Hasler-Strub Ursula, Ruhstaller Thomas, Huober Jens, Mark Michael
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2010
End Date
2012
Financing
Others
Study Design
Phase II
Keywords
Fulvestrant, AZD6244, MEK, 1/2 inhibitor, advanced stage breast cancer, aromatase inhibitor
Homepage
Partner
-
Additional Information
-
Brief description/objective
Einige Krebszellen sind resistent gegenüber klassischer Hormontherapie. AZD6244 ist eine Substanz, welche einen der wichtigsten Resistenzmechanismen blockieren kann.